2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis - secondary publication.

IF 1.8 4区医学 Q3 RHEUMATOLOGY

Modern Rheumatology Pub Date : 2025-01-17 DOI:10.1093/mr/roaf006

Masayoshi Harigai, Yuko Kaneko, Eiichi Tanaka, Shintaro Hirata, Hideto Kameda, Kayoko Kaneko, Mitsumasa Kishimoto, Masataka Kohno, Masayo Kojima, Toshihisa Kojima, Akio Morinobu, Ayako Nakajima, Takahiko Sugihara, Mie Fusama, Nobuyuki Yajima, Ryo Yanai, Yutaka Kawahito

{"title":"2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis - secondary publication.","authors":"Masayoshi Harigai, Yuko Kaneko, Eiichi Tanaka, Shintaro Hirata, Hideto Kameda, Kayoko Kaneko, Mitsumasa Kishimoto, Masataka Kohno, Masayo Kojima, Toshihisa Kojima, Akio Morinobu, Ayako Nakajima, Takahiko Sugihara, Mie Fusama, Nobuyuki Yajima, Ryo Yanai, Yutaka Kawahito","doi":"10.1093/mr/roaf006","DOIUrl":null,"url":null,"abstract":"Objectives: To update the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis (CPG for RA).Methods: The recommendations were developed based on the evidence published until the end of June 2022 using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE). The steering committee, CPG panel, systematic review (SR) group, and SR support team were organised.Results: The treatment goal and drug treatment algorithm required no modifications; however, the footnotes of the drug treatment algorithm were modified. SR of 21 new or updated recommendations for subcutaneous methotrexate (n=1), biological disease-modifying antirheumatic drugs (n=1), rituximab (n=5), Janus kinase inhibitors (n=6), biosimilars (n=2), older patients (n=4), and pregnancy and lactation (n=2) was conducted. The recommendations for comorbidities and surgery and rehabilitation remained unchanged from the 2020 CPG for RA.Conclusion: The 2024 CPG for RA, which provide recommendations that reflect the current healthcare environment for RA in Japan, can be used effectively as a tool for shared decision-making between rheumatologists and patients in the treatment of RA.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mr/roaf006","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To update the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis (CPG for RA).

Methods: The recommendations were developed based on the evidence published until the end of June 2022 using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE). The steering committee, CPG panel, systematic review (SR) group, and SR support team were organised.

Results: The treatment goal and drug treatment algorithm required no modifications; however, the footnotes of the drug treatment algorithm were modified. SR of 21 new or updated recommendations for subcutaneous methotrexate (n=1), biological disease-modifying antirheumatic drugs (n=1), rituximab (n=5), Janus kinase inhibitors (n=6), biosimilars (n=2), older patients (n=4), and pregnancy and lactation (n=2) was conducted. The recommendations for comorbidities and surgery and rehabilitation remained unchanged from the 2020 CPG for RA.

Conclusion: The 2024 CPG for RA, which provide recommendations that reflect the current healthcare environment for RA in Japan, can be used effectively as a tool for shared decision-making between rheumatologists and patients in the treatment of RA.

查看原文本刊更多论文

2024年日本风湿病学会类风湿关节炎管理临床实践指南更新-二次出版。

目的：更新日本风湿病学会类风湿关节炎临床实践指南（CPG for RA）。方法：根据截至2022年6月底公布的证据，使用建议评估、发展和评估分级（GRADE）制定建议。组织了指导委员会、CPG小组、系统评审小组和系统评审支持小组。结果：治疗目标和药物治疗算法无需修改；但是，对药物治疗算法的脚注进行了修改。对21项新的或更新的建议进行了SR分析，包括皮下甲氨蝶呤（n=1）、生物疾病改善抗风湿药物（n=1）、美罗华（n=5）、Janus激酶抑制剂（n=6）、生物仿制药（n=2）、老年患者（n=4）以及妊娠和哺乳期患者（n=2）。对于合并症、手术和康复的建议与2020年RA CPG保持不变。结论：2024年RA CPG提供了反映日本RA当前医疗环境的建议，可以有效地作为风湿病学家和RA治疗患者之间共同决策的工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Modern Rheumatology RHEUMATOLOGY-

CiteScore

4.90

自引率

9.10%

发文量

146

审稿时长

1.5 months

期刊介绍： Modern Rheumatology publishes original papers in English on research pertinent to rheumatology and associated areas such as pathology, physiology, clinical immunology, microbiology, biochemistry, experimental animal models, pharmacology, and orthopedic surgery. Occasional reviews of topics which may be of wide interest to the readership will be accepted. In addition, concise papers of special scientific importance that represent definitive and original studies will be considered. Modern Rheumatology is currently indexed in Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, Academic OneFile, Current Abstracts, Elsevier Biobase, Gale, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions